Serum levels of BMP-2, 4, 7 and AHSG in patients with degenerative joint disease requiring total arthroplasty of the hip and temporomandibular joints

Journal of Orthopaedic Research

Volumn 31, Issue 1, 2013, Pages 44-52

  Albilia, Jonathan B ^a,b,c,d   Tenenbaum, Howard C ^a,b   Clokie, Cameron M L ^a,b   Walt, David R ^a   Baker, Gerald I ^b   Psutka, David J ^b   Backstein, David ^b   Peel, Sean A F ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b MOUNT SINAI HOSPITAL   (Canada)

^c HÔPITAL DU SACRÉ COEUR DE MONTRÉAL   (Canada)

^d 137 100 Chemin Rockland ^*  (Canada)

Author keywords

AHSG Fetuin; arthritis; BMP; hip; TMJ

Indexed keywords

BONE MORPHOGENETIC PROTEIN 2; BONE MORPHOGENETIC PROTEIN 4; FETUIN A; OSTEOGENIC PROTEIN 1;

ADULT; AGED; ARTHROPLASTY; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HIP OSTEOARTHRITIS; HUMAN; MALE; OSTEOARTHRITIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; TEMPOROMANDIBULAR JOINT DISORDER; TEMPOROMANDIBULAR JOINT OSTEOARTHRITIS; TOTAL HIP PROSTHESIS; TOTAL TEMPOROMANDIBULAR JOINT ARTHROPLASTY;

ADULT; AGED; AGED, 80 AND OVER; ALPHA-2-HS-GLYCOPROTEIN; ARTHROPLASTY, REPLACEMENT; ARTHROPLASTY, REPLACEMENT, HIP; BIOLOGICAL MARKERS; BONE MORPHOGENETIC PROTEIN 2; BONE MORPHOGENETIC PROTEIN 4; BONE MORPHOGENETIC PROTEIN 7; BONE MORPHOGENETIC PROTEINS; FEMALE; HUMANS; MALE; MIDDLE AGED; OSTEOARTHRITIS, HIP; PREDICTIVE VALUE OF TESTS; PREOPERATIVE CARE; SEVERITY OF ILLNESS INDEX; TEMPOROMANDIBULAR JOINT DISORDERS; YOUNG ADULT;

EID: 84870236561     PISSN: 07360266     EISSN: 1554527X     Source Type: Journal    
DOI: 10.1002/jor.22182     Document Type: Article

References (31)

1. Luyten FP., 2004. Mesenchymal stem cells in osteoarthritis. Curr Opin Rheumatol 16: 599-603.
2. Chubinskaya S, Frank BS, Michalska M, et al. 2006. Osteogenic protein 1 in synovial fluid from patients with rheumatoid arthritis or osteoarthritis: relationship with disease and levels of hyaluronan and antigenic keratan sulfate. Arthritis Res Ther 8: R73.
3. Kraus VB, Nevitt M, Sandell LJ., 2010. Summary of the OA biomarkers workshop 2009 - biochemical biomarkers: biology, validation, and clinical studies. Osteoarthr Cartilage 18: 742-745.
4. Suzuki T, Bessho K, Segami N, et al. 1999. Bone morphogenetic protein-2 in temporomandibular joints with internal derangement. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 88: 670-673.
5. Herrera B, Inman GJ., 2009. A rapid and sensitive bioassay for the simultaneous measurement of multiple bone morphogenetic proteins. Identification and quantification of BMP4, BMP6 and BMP9 in bovine and human serum. BMC Cell Biol 10: 20.
6. Goldring MB., 2006. Update on the biology of the chondrocyte and new approaches to treating cartilage diseases. Best Pract Res Clin Rheumatol 20: 1003-1025.
7. Lories RJ, Daans M, Derese I, et al. 2006. Noggin haploinsufficiency differentially affects tissue responses in destructive and remodeling arthritis. Arthritis Rheum 54: 1736-1746.
8. Erlacher L, Ng CK, Ullrich R, et al. 1998. Presence of cartilage-derived morphogenetic proteins in articular cartilage and enhancement of matrix replacement in vitro. Arthritis Rheum 41: 263-273.
9. Chubinskaya S, Hurtig M, Rueger DC., 2007. OP-1/BMP-7 in cartilage repair. Int Orthop 31: 773-781.
10. Harrison ET, Jr., Luyten FP, Reddi AH., 1992. Transforming growth factor-beta: its effect on phenotype reexpression by dedifferentiated chondrocytes in the presence and absence of osteogenin. In Vitro Cell Dev Biol 28A: 445-448.
11. Aspenberg P, Forslund C., 1999. Enhanced tendon healing with GDF 5 and 6. Acta Orthop Scand 70: 51-54.
12. Neuwirth J, Fuhrmann RA, Veit A, et al. 2006. Expression of bioactive bone morphogenetic proteins in the subacromial bursa of patients with chronic degeneration of the rotator cuff. Arthritis Res Ther 8: R92.
13. Serra R, Johnson M, Filvaroff EH, et al. 1997. Expression of a truncated, kinase-defective TGF-beta type II receptor in mouse skeletal tissue promotes terminal chondrocyte differentiation and osteoarthritis. J Cell Biol 139: 541-552.
14. Sato H, Kazama JJ, Wada Y, et al. 2007. Decreased levels of circulating alpha2-Heremans-Schmid glycoprotein/Fetuin-A (AHSG) in patients with rheumatoid arthritis. Intern Med 46: 1685-1691.
15. Branton MH, Kopp JB., 1999. TGF-beta and fibrosis. Microbes Infect 1: 1349-1365.
16. van der Kraan PM, van den Berg WB., 2007. Osteophytes: relevance and biology. Osteoarthr Cartilage 15: 237-244.
17. Suzuki K, Kawachi S, Sakai H, et al. 2004. Mini-incision total hip arthroplasty: a quantitative assessment of laboratory data and clinical outcomes. J Orthop Sci 9: 571-575.
18. Nordahl S, Alstergren P, Eliasson S, et al. 2001. Radiographic signs of bone destruction in the arthritic temporomandibular joint with special reference to markers of disease activity. A longitudinal study. Rheumatology (Oxford) 40: 691-694.
19. Demetriou M, Binkert C, Sukhu B, et al. 1996. Fetuin/alpha2-HS glycoprotein is a transforming growth factor-beta type II receptor mimic and cytokine antagonist. J Biol Chem 271: 12755-12761.
20. So A, Chamot AM, Peclat V, et al. 1999. Serum MMP-3 in rheumatoid arthritis: correlation with systemic inflammation but not with erosive status. Rheumatology (Oxford) 38: 407-410.
21. Chubinskaya S, Kumar B, Merrihew C, et al. 2002. Age-related changes in cartilage endogenous osteogenic protein-1 (OP-1). Biochim Biophys Acta 1588: 126-134.
22. Fukui N, Zhu Y, Maloney WJ, et al. 2003. Stimulation of BMP-2 expression by pro-inflammatory cytokines IL-1 and TNF-alpha in normal and osteoarthritic chondrocytes. J Bone Joint Surg Am 85-A: 59-66.
23. Loeser RF, Pacione CA, Chubinskaya S., 2003. The combination of insulin-like growth factor 1 and osteogenic protein 1 promotes increased survival of and matrix synthesis by normal and osteoarthritic human articular chondrocytes. Arthritis Rheum 48: 2188-2196.
24. Jelic M, Pecina M, Haspl M, et al. 2001. Regeneration of articular cartilage chondral defects by osteogenic protein-1 (bone morphogenetic protein-7) in sheep. Growth Factors 19: 101-113.
25. Rittenberg B, Partridge E, Baker G, et al. 2005. Regulation of BMP-induced ectopic bone formation by Ahsg. J Orthop Res 23: 653-662.
26. Groppe J, Greenwald J, Wiater E, et al. 2002. Structural basis of BMP signalling inhibition by the cystine knot protein Noggin. Nature 420: 636-642.
27. Wang H, Zhang M, Bianchi M, et al. 1998. Fetuin (alpha2-HS-glycoprotein) opsonizes cationic macrophagedeactivating molecules. Proc Natl Acad Sci USA 95: 14429-14434.
28. Baskies AM, Chretien PB, Weiss JF, et al. 1980. Serum glycoproteins in cancer patients: first report of correlations with in vitro and in vivo parameters of cellular immunity. Cancer 45: 3050-3060.
29. Wang H, Zhang M, Soda K, et al. 1997. Fetuin protects the fetus from TNF. Lancet 350: 861-862.
30. Ombrellino M, Wang H, Yang H, et al. 2001. Fetuin, a negative acute phase protein, attenuates TNF synthesis and the innate inflammatory response to carrageenan. Shock 15: 181-185.
31. Wang H, Lam L, Li W, et al. 2010. Fetuin protects mice against lethal sepsis by modulating bacterial endotoxin-induced hmgb1 release and autophagy. Shock 33: 6-7.